(lp0
S'Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences PR Newswire  - Mar 6, 2017 WASHINGTON, March 6, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc.   today announced that it will participate at the following upcoming investor conferences in March 2017.Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces Participation at ... - The Wall Street TranscriptVanda Pharmaceuticals Inc.  Median Target At $22 - Markets Daily'
p1
aS'Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial ... PR Newswire  - Jan 19, 2017 To participate in the conference call, please dial 1-888-771-4371  or 1-847-585-4405  and use passcode 44159815.'
p2
aS"Vanda Pharmaceuticals'  CEO Mihael Polymeropoulos on Q4 2016 Results ... Seeking Alpha - Feb 16, 2017 Welcome to the Q4 2016 Vanda Pharmaceuticals Inc. Earnings Conference Call. My name is Victoria and I will be your operator for today's call.Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial ... - PR Newswire Vanda Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 17 - Equities.com"
p3
aS'Vanda Pharmaceuticals Settles Fanapt Patent Litigation with Taro PR Newswire  - Oct 24, 2016 WASHINGTON, Oct. 24, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc.   today announced it has entered into a License Agreement  with Taro Pharmaceuticals U.S.'
p4
aS'Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial ... PR Newswire  - Feb 10, 2016 10, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc.  , today announced financial and operational results for the fourth quarter and full year ended December 31, 2015.'
p5
aS'Vanda Pharmaceuticals Inc.  Soars 6.39% on January 31 Equities.com - Jan 31, 2017 Vanda Pharmaceuticals Inc.  had a good day on the market for Tuesday January 31 as shares jumped 6.39% to close at $14.15.'
p6
aS'Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial ... PR Newswire  - Dec 17, 2015 WASHINGTON, Dec. 17, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc.   today announced that it has appointed Gian Piero Reverberi to the role of Senior Vice President, Acting Chief Commercial Officer and European General&nbsp;...'
p7
aS"Vanda Pharmaceuticals'  CEO Mihael Polymeropoulos on Q3 2016 Results ... Seeking Alpha - Nov 3, 2016 Welcome to the Q3 2016 Vanda Pharmaceuticals, Inc. Earnings Conference Call. My name is Ashley and I will be your operator for today's call."
p8
aS'Birchview Capital, LP Buys Veracyte, Vanda Pharmaceuticals, Aevi Genomic ... Nasdaq - Feb 10, 2017 Birchview Capital, LP initiated holdings in Vanda Pharmaceuticals Inc. The purchase prices were between $13.65 and $17.63, with an estimated average price of $16.07.'
p9
aS"VANDA PHARMACEUTICALS INC.  Files An 8-K Departure of Directors ... Market Exclusive - Mar 13, 2017 On March 8, 2017, Paolo Baroldi, M.D. notified Vanda Pharmaceuticals Inc.  of his resignation as the Company's Chief Medical Officer effective as of March 22, 2017."
p10
a.